Hospital del Mar Research Institute Hospital del Mar Research Institute

News

13/11/2026 - General information

Progress in improving the diagnosis of metabolic dysfunction-associated steatotic liver disease in people with type 1 diabetes mellitus

A new study led by the Endocrinology Department at Hospital del Mar, published in The Journal of Clinical Endocrinology & Metabolism, has identified simple and accessible tools to identify patients with this condition and distinguish it from glycogenic hepatopathy, a different and reversible disease.

The Endocrinology Department at Hospital del Mar has recently published a new study representing a step forward in the rapid diagnosis of metabolic dysfunction-associated steatotic liver disease, commonly known as metabolic fatty liver disease, in patients with type 1 diabetes mellitus. This is an important advance, as it will help distinguish which patients have this condition, which can be confused with another disease, glycogenic hepatopathy, when using certain diagnostic tests. This will help improve diagnosis and provide patients with individualized follow-up. The study has been published in The Journal of Clinical Endocrinology & Metabolism.

Both diseases have different causes and prognoses, although they may appear similar on ultrasound imaging. Metabolic dysfunction-associated steatotic liver disease can progress to advanced liver disease, whereas glycogenic hepatopathy is potentially reversible with improved glycemic control. This highlights the importance of having reliable diagnostic tools.

The study involved 202 adults with type 1 diabetes mellitus. Participants underwent a clinical assessment, blood tests and a liver ultrasound. In cases where the ultrasound showed abnormalities, the assessment was supplemented with magnetic resonance imaging (MRI), which made it possible to quantify liver fat. Various diagnostic indices and blood biomarkers were also analyzed.

The results indicate that "ultrasound may overestimate the presence of hepatic steatosis in people with type 1 diabetes mellitus", explains Dr. Silvia Ballesta, a physician in the Endocrinology and Nutrition Department and a researcher in the Cardiovascular Risk and Nutrition Research Group at the Hospital del Mar Research Institute (HMRIB). The study found that only half of the participants with abnormal ultrasound findings who underwent MRI showed an accumulation of liver fat. In contrast, the Fatty Liver Index (FLI), calculated using clinical data and routine blood tests, "showed a good ability to identify the condition in participants assessed by MRI", adds Dr. Gemma Llauradó, a physician in the Endocrinology and Nutrition Department and a researcher at HMRIB and the CIBER area for Diabetes and Associated Metabolic Diseases (CIBERDEM). She also points out that associations were identified with other metabolic biomarkers, namely pyruvate and succinate.

Better diagnostic tools

Dr. Juan José Chillarón, Head of Section in the Endocrinology and Nutrition Department and a researcher at HMRIB and the CIBER area for Epidemiology and Public Health (CIBERESP), states that having "simple and accessible tools such as the FLI could help identify which patients with abnormal ultrasound findings require additional examinations, promoting more accurate diagnosis and individualized follow-up". Nevertheless, the results need to be validated in larger studies, and further research is required to explore the usefulness of the identified biomarkers. At the same time, strategies must be developed to better distinguish between the accumulation of fat and glycogen in the liver.

Researchers from the Consorci Sanitari de l'Alt Penedès-Garraf, Hospital Universitari Joan XXIII, Institut de Recerca Biomèdica Catalunya Sud (IRB CatSud), Universitat Rovira i Virgili and Universitat Autònoma de Barcelona also participated in the study.

The two conditions studied have different origins and prognoses. Metabolic dysfunction-associated steatotic liver disease is mainly associated with obesity, insulin resistance and a higher cardiometabolic risk. In contrast, glycogenic hepatopathy is linked to impaired glycemic control and generally has a more favorable prognosis.

Reference article

Ballesta S, Pedro-Botet J, Climent E, Fernández-Veledo S, Gaja R, Garrido A, Vendrell J, Sánchez J, Fernández M, Chillarón JJ, Llauradó G. Clinical and non-invasive assessment of metabolic dysfunction-associated steatotic liver disease and glycogenic hepatopathy in individuals with type 1 diabetes. J Clin Endocrinol Metab. 2026 Oct 10. doi: 10.1210/clinem/dgag422. Epub ahead of print. PMID: 42857930.

More news

Contact

Servei de Comunicació:
Marta Calsina(ELIMINAR)

Tel:
(+34) 93 316 06 80

Doctor Aiguader, 88
08226 Barcelona

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact